SmartPeptide
Start Free
RecoveryAnimal / preclinical only

BPC-157

A pentadecapeptide derived from a sequence in human gastric juice. Most existing data is preclinical (animal models), exploring tissue repair, gut barrier, and tendon healing.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Multiple animal studies (rats, mice) show accelerated tendon, ligament, and gut-mucosa healing. Mechanism appears to involve angiogenesis and growth-factor expression.

What's still experimental

Almost zero rigorous human RCTs. Anti-inflammatory and joint-recovery claims in humans are extrapolated from animal data and have not been independently replicated in well-controlled trials.

Anecdotal / community reports

Widespread biohacker reports of faster injury recovery and gut comfort. These reports are inconsistent and uncontrolled.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “BPC-157”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
Total actions
6
recalls + withdrawals
Ongoing
3
not yet completed
Class I (serious)
0
health hazard / death risk
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    BPC-157 for Injection, 15mg/10mL vial, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Medical Health Institute (MHI), 15mg, 10m…

    Reason: Lack of Assurance of Sterility

    Jul 30, 2025·GenoGenix LLC
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    BPC-157/Thymosin Beta-4 for Injection, a) 10/10mg, b) 15/15mg, c) 15mg/15mg, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for CELI…

    Reason: Lack of Assurance of Sterility

    Jul 30, 2025·GenoGenix LLC
  • Class IITerminated· Voluntary: Firm initiated
    FDA record

    BPC-157 2 mg/mL (5 mL) Injection, 5 mL vials, Rx Only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081

    Reason: Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

    Apr 5, 2022·North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    BPC-157, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN

    Reason: Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

    Nov 30, 2020·Advanced Nutriceuticals, LLC
  • Class IITerminated· Voluntary: Firm initiated
    FDA record

    BPC-157 2000 mcg/mL in 5 mL vials Assurance Infusion (713) 533-8800

    Reason: Lack of sterility assurance.

    Dec 20, 2019·Assurance Infusion
FDA classifications: Class I = reasonable probability of serious adverse health consequences or death. Class II = temporary or medically reversible adverse consequences. Class III = unlikely to cause adverse health consequences.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Formula
C62H98N16O22

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
222
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
1
2 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "BPC-157"

Europe PMC — 814 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
4,794
all years
Last 5 years
2,315
recent activity
Open access
4,333
freely readable
OA share
90%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Total indexed
111,634
all human + lab studies
Meta-analyses
0
highest evidence
Systematic reviews
15
quality-weighted
Clinical trials
0
published RCTs etc.

Most influential human studies

Ranking blends meta-analysis > systematic review > clinical trial weight with influential-citation count and recency. AI TLDRs by Semantic Scholar / Allen Institute for AI.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

NIH-funded research

U.S. National Institutes of Health
Funded projects
1,670
all years
Top award sum
$456.4M
aggregate USD
Years covered
24
research span
Largest active / recent grants

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
536,261
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China6,014 works
  • National Institutes of Health1,070 works
  • National Science Foundation989 works
  • National Key Research and Development Program of China690 works
  • Fundamental Research Funds for the Central Universities669 works
  • National Research Foundation of Korea544 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 12 preprints indexed by Europe PMC.

Known risks

Human safety data is limited. Long-term effects are unknown. Regulatory status varies by region.

Reported side effects

Reported anecdotally: localized irritation at injection sites, headaches. No robust clinical safety profile exists.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
Reports filed
15
FAERS, all years
Serious reports
14
93% of reports
Top reporting countries
  • US7
  • CA1

Most-reported reactions

  • Drug Ineffective
    3
  • Abdominal Discomfort
    2
  • Balance Disorder
    2
  • Drug Intolerance
    2
  • Dyspnoea
    2
  • Erythema
    2
  • Flushing
    2
  • Headache
    2
  • Hypersensitivity
    2
  • Nausea
    2

Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs

What requires medical supervision

Not approved by the FDA. Long-term safety unknown. Anyone considering use should discuss with a clinician familiar with off-label peptides — especially if pregnant, immunocompromised, or on other medications.

Questions for your clinician

  • What human evidence exists for BPC-157 in my specific situation?
  • What baseline labs should we run before and during use?
  • What signs of harm should I watch for?
  • Are there better-studied alternatives for my recovery goal?

Editorially curated references

Discussions about BPC-157

Start a discussion
See all BPC-157 discussions Native, moderated, no buying or selling